Felipe Maegawa

BACKGROUND: Despite the advances in the multidisciplinary treatment of gastric adenocarcinoma, the overall 5-year survival remains only 33.3% in North America. R0 resection with adequate lymphadenectomy remains the mainstay therapy…

BACKGROUND: The safety of robotic cholecystectomy remains a topic of intense debate. Data on robotic cholecystectomy is now available in the NSQIP 2022 Participant Use Data File (PUF). Herein, we evaluate the safety of robotic vs laparoscopic cholecystectomy…